Akoustis Technologies, Inc. (AKTS) Ownership
AKTS ownership summary
as of October 18, 2026- Institutions
- 73.2% of shares outstanding
- Insiders
- 14.05% of shares outstanding
- Shares outstanding
- 53.7M
- Float
- 28.6M shares available to trade
- Short interest
- 29.16% 4.7M shares short
- Days to cover
- 10.11 short interest up 45.0% vs prior month
- Institutions 73.19%
- Insiders 14.05%
- Other investors 12.76%
AKTS top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | MPM Oncology Impact Management LP | 8.69% | 4.8M | $72.8M | — | June 30, 2026 |
| 2 | EcoR1 Capital, LLC | 8.67% | 4.8M | $72.7M | — | June 30, 2026 |
| 3 | Blue Owl Capital Holdings LP | 5.52% | 3.1M | $46.2M | −91,129 (−2.9%) | June 30, 2026 |
| 4 | BlackRock Inc | 4.10% | 2.3M | $34.3M | +166,231 (+7.9%) | June 30, 2026 |
| 5 | T. Rowe Price Investment Management,Inc. | 3.69% | 2.1M | $30.9M | −72,365 (−3.4%) | June 30, 2026 |
| 6 | Wellington Management Company LLP | 3.54% | 2.0M | $29.6M | −350,800 (−15.1%) | June 30, 2026 |
| 7 | RTW INVESTMENTS, LLC | 2.86% | 1.6M | $24.0M | — | June 30, 2026 |
| 8 | HHG PLC | 2.61% | 1.5M | $21.9M | +1.5M (0.0%) | March 31, 2026 |
| 9 | RA Capital Management, LLC | 2.36% | 1.3M | $19.8M | −188,679 (−12.6%) | June 30, 2026 |
| 10 | Jupiter Topco LLC | 2.36% | 1.3M | $19.8M | +1.3M (0.0%) | June 30, 2026 |
| 11 | Baker Bros Advisors LP | 1.79% | 996K | $15.0M | — | June 30, 2026 |
| 12 | Octagon Capital Advisors LP | 1.73% | 961K | $14.5M | — | June 30, 2026 |
| 13 | Merck & Co Inc | 1.71% | 953K | $14.3M | — | June 30, 2026 |
| 14 | Vanguard Capital Management, LLC | 1.47% | 817K | $12.3M | −16,838 (−2.0%) | June 30, 2026 |
| 15 | T. Rowe Price Associates, Inc. | 1.37% | 763K | $11.5M | −800,697 (−51.2%) | June 30, 2026 |
| 16 | TCG Crossover Management, LLC | 1.25% | 697K | $10.5M | +696,560 (0.0%) | June 30, 2026 |
| 17 | Geode Capital Management, LLC | 0.94% | 521K | $7.8M | +28,801 (+5.9%) | June 30, 2026 |
| 18 | Eventide Asset Management, LLC | 0.91% | 507K | $7.6M | — | June 30, 2026 |
| 19 | Avidity Partners Management LP | 0.87% | 484K | $7.3M | −452,932 (−48.3%) | June 30, 2026 |
| 20 | State Street Corp | 0.87% | 484K | $7.3M | +55,757 (+13.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 6 holders added 3.7M shares and 7 cut 2.0M.
AKTS top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard Health Care Inv | 3.51% | 2.0M | $29.4M | −70,300 (−3.5%) | June 30, 2026 |
| 2 | T. Rowe Price Small-Cap Stock | 2.14% | 1.2M | $17.9M | −793 (−0.1%) | August 31, 2026 |
| 3 | iShares Russell 2000 ETF | 1.31% | 731K | $11.0M | −8,448 (−1.1%) | September 30, 2026 |
| 4 | T. Rowe Price Health Sciences | 1.25% | 694K | $10.5M | −364,600 (−34.4%) | August 31, 2026 |
| 5 | T. Rowe Price Instl Small-Cap Stock | 1.15% | 638K | $9.6M | — | August 31, 2026 |
| 6 | Vanguard MStar Total Stk Mkt Idx Invest | 1.05% | 585K | $8.8M | — | August 31, 2026 |
| 7 | State Street® SPDR® S&P® Biotech ETF | 0.92% | 513K | $7.7M | −9,800 (−1.9%) | September 30, 2026 |
| 8 | Eventide Healthcare & Life Sciences I | 0.91% | 507K | $7.6M | — | June 30, 2026 |
| 9 | BGF World Healthscience A2 | 0.67% | 373K | $5.6M | — | June 30, 2026 |
| 10 | Fidelity Select Biotechnology | 0.51% | 283K | $4.3M | — | August 31, 2026 |
| 11 | BlackRock Health Sciences Opps Inv A | 0.48% | 267K | $4.0M | — | August 31, 2026 |
| 12 | Fidelity Small Cap Index | 0.42% | 232K | $3.5M | +2,609 (+1.1%) | July 31, 2026 |
| 13 | T. Rowe Price Small-Cap Value | 0.40% | 224K | $3.4M | −2,056 (−0.9%) | August 31, 2026 |
| 14 | T. Rowe Price US Smlr Coms Eq A | 0.38% | 209K | $3.1M | −6,602 (−3.1%) | August 31, 2026 |
| 15 | iShares Russell 2000 Growth ETF | 0.33% | 183K | $2.8M | −232 (−0.1%) | September 30, 2026 |
| 16 | T. Rowe Price New Horizons | 0.32% | 179K | $2.7M | −7,322 (−3.9%) | August 31, 2026 |
| 17 | Schwab US Small-Cap ETF™ | 0.24% | 134K | $2.0M | +90 (+0.1%) | September 30, 2026 |
| 18 | Vanguard Russell 2000 ETF | 0.22% | 122K | $1.8M | +2,801 (+2.4%) | August 31, 2026 |
| 19 | Meridian Small Cap Growth Legacy | 0.19% | 106K | $1.6M | — | June 30, 2026 |
| 20 | Fidelity Extended Market Index | 0.17% | 93K | $1.4M | −45 (−0.0%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
AKTS insider transactions
latest 5| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-12 | Ansbert Gadicke | Buy | $18.00 | 1,112,777 | $20.0M |
| 2026-01-12 | Bioventures 2018 L.P. Mpm | Buy | $18.00 | 1,112,777 | $20.0M |
| 2026-01-12 | Ecor1 Capital, Llc | Buy | $18.00 | 2,222,222 | $40.0M |
| 2026-01-12 | Helen Susan Kim | Buy | $18.00 | 835,000 | $15.0M |
| 2026-01-12 | Vida Ventures Ii, Llc | Buy | $18.00 | 835,000 | $15.0M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
AKTS shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns AKTS
Institutional investors own 73.2% of Akoustis Technologies's shares and insiders 14.05%. The largest holder is MPM Oncology Impact Management LP with 8.69% of the shares (4.8M), as of June 30, 2026. Among the top 20 institutions, 6 added shares and 7 reduced their stake in the latest filings. Short interest is 29.16% of the float, or 10.11 days of average trading volume. The share count rose 315.5% since 2014.
Related: AKTS analyst forecast, AKTS key metrics. See the AKTS stock overview for the latest quote and news.
AKTS ownership FAQ
Who owns the most Akoustis Technologies stock?
The largest shareholders of Akoustis Technologies are MPM Oncology Impact Management LP (8.69%), EcoR1 Capital, LLC (8.67%), Blue Owl Capital Holdings LP (5.52%), BlackRock Inc (4.10%), T. Rowe Price Investment Management,Inc. (3.69%).
What percentage of Akoustis Technologies is owned by institutions?
Institutions hold 73.2% of Akoustis Technologies's shares outstanding; insiders hold 14.05%.
Which funds own Akoustis Technologies?
The largest fund holders of Akoustis Technologies are Vanguard Health Care Inv (3.51%), T. Rowe Price Small-Cap Stock (2.14%), iShares Russell 2000 ETF (1.31%), T. Rowe Price Health Sciences (1.25%), T. Rowe Price Instl Small-Cap Stock (1.15%).
What is Akoustis Technologies's short interest?
4.7M shares of Akoustis Technologies were sold short, 29.16% of the float; at the average daily volume it would take 10.11 days to cover.
Are insiders buying or selling Akoustis Technologies?
Of the latest 5 reported insider transactions in Akoustis Technologies (since January 12, 2026), 5 were purchases and 0 were sales.
How many shares of Akoustis Technologies are outstanding?
Akoustis Technologies has 53.7M shares outstanding, of which 28.6M are in the public float.